您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Vigabatrin-13C-d2(hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vigabatrin-13C-d2(hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vigabatrin-13C-d2(hydrochloride)图片
规格:98%
分子量:168.6
包装与价格:
包装价格(元)
500ug电议
1mg电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx23726
CAS:N/A
分子式:C5[13C]H9D2NO2.HCl
分子量:168.6
溶解度:Water: soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Vigabatrin-13C-d2is intended for use as an internal standard for the quantification of vigabatrin by GC- or LC-MS. Vigabatrin is an irreversible GABA transaminase (GABA-T) inhibitor.1It inhibits rat brain GABA-T when used at a concentration of 0.1 mM. Vigabatrin is selective for rat brain GABA-T overP. fluorescensGABA-T at 10 mM and is 100-fold selective over glutamic acid decarboxylase (GAD). Vigabatrin (1,500 mg/kg) decreases brain GABA-T activity without affecting GAD activity in mice.2It reduces the incidence of myoclonus in a mouse model of audiogenic seizures.3Vigabatrin also increases the electroconvulsive threshold in mouse model of maximal electroshock-induced seizures and reduces the number of clonic convulsions induced by pentylenetetrazol in mice.4Formulations containing vigabatrin have been used in the treatment of seizures and infantile spasms.


1.Lippert, B., Metcalf, B.W., Jung, M.J., et al.4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brainEur. J. Biochem.74(3)441-445(1977) 2.Jung, M.J., Lippert, B., Metcalf, B.W., et al.g-Vinyl GABA (4-amino-hex-5-enoic acid), A new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in miceJ. Neurochem.29(5)797-802(1977) 3.Meldrum, B.S., and Murugaiah, K.Anticonvulsant action in mice with sound-induced seizures of the optical isomers of g-vinyl GABAEur. J. Pharm.89(1-2)149-152(1983) 4.Luszczki, J.J., and Czuczwar, S.J.Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsyProg. Neuropsychopharmacol. Biol. Psychiatry31(2)529-538(2007)